Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDK378 versus standard chemotherapy in previously untreated ALK-positive advanced non-squamous NSCLC
NL-OMON55921Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ceritinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Dec 2013; status: completed.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55921.